News | Nuclear Imaging | February 14, 2020

APAC Nuclear Imaging Market Projected to Grow at CAGR of 8.9%

GlobalData projects this growth to occur between 2019 and 2028 

Nuclear imaging equipment growth in 2020

February 14, 2020 — The nuclear imaging equipment market in the Asia-Pacific (APAC) region is expected to grow at a compound annual growth rate (CAGR) of 8.9 percent from US$0.7B in 2019 to US$1.5B by 2028, according to GlobalData, a leading data and analytics company.

China will be by far the fastest growing country in the region growing at a CAGR of 11.0 percent between 2019 and 2028, which is closely followed by the fastest growing markets: India, South Korea and Japan, respectively.

The company’s report, ‘Nuclear Imaging Equipment – Diagnostic Imaging Market Analysis and Forecast Model’ states that while inclination toward non-invasive disease diagnosis will be the main market driver, the increased aging population with cardiac and neurological ailments and growing cancer patients in both younger and older population will propel the market during the forecast period.

 

Sirivolu Manasa, medical devices analyst at GlobalData, commented: “GE Healthcare has remained as the market leader in APAC due to its innovation of advanced technologies by acknowledging the requirements of the patients. Regional companies like Canon Medical Systems Corp and Neusoft Medical Systems have also established themselves as competitors in this space apart from the other global manufacturers such as Siemens Healthineers AG and Philips Healthcare.”

 

In the APAC region, positron emission tomography/computed tomography (PET/CT) systems are the major revenue contributors within CT systems, with their market growing at a CAGR of 8.8 percent between 2019 and 2028, followed by single photon emission computed tomography/computed tomography (SPECT /CT) systems.

 

Manasa concluded: “The technological advancements in the medical field will have a positive impact on the growth of nuclear imaging equipment market. The demand for the products required specifically for each of the vital organs will help physicians make more accurate clinical decisions enhancing patient safety, driving the market forward.”

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
 “Cyclotrons used in Nuclear Medicine Report & Directory, Edition 2020” that describes close to 1,500 medical cyclotrons worldwide
News | Nuclear Imaging | March 10, 2020
March 10, 2020 — MEDraysintell released its new and unique report “...
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy